Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
Gastric Cancer · 2024-11 · 27 (6) · 1287-1301
DOI: 10.1007/s10120-024-01535-0 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Gastric Cancer, online erschienen am 20.08.2024. Verfasst von Narikazu Boku und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, Esophagogastric Junction. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K..
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Nivolumab + chemotherapy is now a standard of care for HER2-negative, previously untreated, unresectable or recurrent gastric/gastroesophageal junction cancer (advanced gastric cancer), but long-term follow-up data of clinical trials are limited.
Methods
ATTRACTON-4 was a phase 3, double-blind, placebo-controlled trial in Japan, South Korea, and Taiwan. Patients were randomized to either nivolumab or placebo, both combined with the physician’s choice of SOX (oral S-1 [tegafur–gimeracil–oteracil potassium] + oxaliplatin) or CAPOX (capecitabine + oxaliplatin). We report the primary endpoints—centrally assessed progression-free survival (PFS) and overall survival (OS)—and landmark analyses of OS among patients alive using 3-year follow-up data.
Results
At the cutoff date (May 10, 2021), 17/359 patients in the nivolumab + chemotherapy group and 6/358 in the placebo + chemotherapy group were continuing study treatment. PFS (centrally assessed) was longer in the nivolumab + chemotherapy group (median 10.94 vs. 8.48 months; hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.55–0.82). Although OS did not differ between the two groups (median 17.45 vs. 17.15 months; HR 0.89, 95% CI 0.75–1.05), the landmark analysis of OS, calculating HRs at each landmark time point (every month), was getting numerically better in the nivolumab + chemotherapy group over time. Approximately 80% of patients who achieved complete response in the nivolumab + chemotherapy group were alive at 3 years. No new safety signals or major late-onset select treatment-related adverse events were observed for nivolumab + chemotherapy.
Conclusion
This 3-year follow-up of ATTRACTION-4 confirmed the long-term clinical benefit and manageable safety of nivolumab + chemotherapy in patients with previously untreated advanced gastric cancer.
Trial registration
NCT02746796
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
- Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Saitama Medical University International Medical Center, Hidaka, Japan.
- Department of Gastroenterological Chemotherapy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
- Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
ORCID-Profile: Yoon-Koo Kang
Förderung
- Ono Pharmaceutical Co., Ltd.
- Bristol-Myers Squibb K.K.
Zitieren
APA
Boku, N., Omori, T., Shitara, K., Sakuramoto, S., Yamaguchi, K., Kato, K., Kadowaki, S., Tsuji, K., Ryu, M. H., Oh, D. Y., Oh, S. C., Rha, S. Y., Lee, K. W., Chung, I. J., Sym, S. J., Chen, L. T., Chen, J. S., Bai, L. Y., Nakada, T., …, & Kang, Y. K. (2024). Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial. Gastric Cancer, 27(6), 1287-1301. https://doi.org/10.1007/s10120-024-01535-0
Vancouver
Boku N, Omori T, Shitara K, Sakuramoto S, Yamaguchi K, Kato K, et al. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial. Gastric Cancer. 2024;27(6):1287-1301. doi:10.1007/s10120-024-01535-0
BibTeX
@article{Boku2024,
author = {Boku, Narikazu and Omori, Takeshi and Shitara, Kohei and Sakuramoto, Shinichi and Yamaguchi, Kensei and Kato, Ken and Kadowaki, Shigenori and Tsuji, Kunihiro and Ryu, Min-Hee and Oh, Do-Youn and Oh, Sang Cheul and Rha, Sun Young and Lee, Keun-Wook and Chung, Ik-Joo and Sym, Sun Jin and Chen, Li-Tzong and Chen, Jen-Shi and Bai, Li-Yuan and Nakada, Takashi and Hagihara, Shunsuke and Makino, Reina and Nishiyama, Eiji and Kang, Yoon-Koo},
title = {Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial},
journal = {Gastric Cancer},
year = {2024},
volume = {27},
number = {6},
pages = {1287--1301},
doi = {10.1007/s10120-024-01535-0}
}
EUVIMED